Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells
Mesenchymal stromal cells (MSCs) have been established as promising candidate sources of universal donor cells for cell therapy due to their contributions to tissue and organ homeostasis, repair, and support by self-renewal and multidifferentiation, as well as by their anti-inflammatory, antiprolife...
Saved in:
Main Authors: | Natalia Escacena, Elena Quesada-Hernández, Vivian Capilla-Gonzalez, Bernat Soria, Abdelkrim Hmadcha |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2015/895714 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
FUND OF ELIMINATION OF BOTTLENECKS
by: T. Gataullin, et al.
Published: (2016-01-01) -
The Clinical Trials of Mesenchymal Stromal Cells Therapy
by: Mohammad Reza Kouchakian, et al.
Published: (2021-01-01) -
Advancing Model Explainability: Visual Concept Knowledge Distillation for Concept Bottleneck Models
by: Ju-Hwan Lee, et al.
Published: (2025-01-01) -
Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury
by: Pascal Rowart, et al.
Published: (2015-01-01) -
Pharmaceuticals: Placebo in combating bottlenecks
by: Katharina Blankart, et al.
Published: (2022-04-01)